Pankaj Jariwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pankaj Jariwala has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Arshad Punjani
13 shared publications- Kartik Pandurang Jadhav
Department of Cardiology, Apollo Hospital, Hyderabad, Telangana, India
13 shared publications Satya Sridhar Kale
Department of Cardiothoracic Surgery, Yashoda Hospitals, Hyderabad, Telangana, India
11 shared publicationsDilip Babu Madhawar
Department of Nephrology and Transplant Medicine, Yashoda Hospitals, Hyderabad, Telangana, India
8 shared publicationsDilip Gude
8 shared publicationsGururaj Pramod Kulkarni
8 shared publications
Latest Publications
- Open Access
- 29 December 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 62, 100703
Short dual antiplatelet therapy after PCI with Resolute Onyx drug-eluting stents in high bleeding risk patients: One-year outcomes from a South Asian cohort
- 29 December 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 62, 100703
Open AccessShort dual antiplatelet therapy after PCI with Resolute Onyx drug-eluting stents in high bleeding risk patients: One-year outcomes from a South Asian cohort
- Open Access
- 9 December 2025
- Published by Georg Thieme Verlag KG in Journal of Clinical Interventional Radiology ISVIR
- Vol. 10 (01) , 004-011
Percutaneous Endovascular Approach to Symptomatic High-Grade Subclavian Artery Stenosis: A Retrospective Analysis
Subclavian artery stenosis (SAS) commonly causes upper limb ischemia and cerebrovascular insufficiency. Percutaneous transluminal angioplasty (PTA) and stenting have emerged as the preferred minimally invasive alternatives to surgical revascularization. This study aimed to evaluate the safety, efficacy, and midterm outcomes of antegrade and retrograde endovascular approaches for symptomatic SAS. This retrospective single-center analysis included 75 patients (45 men and 30 women; mean age, 65.3 years) treated between 2015 and 2023. The average follow-up period was 33.6 months (range, 20–52). The clinical characteristics, procedural techniques, and outcomes were retrospectively reviewed and analyzed. Technical success was achieved in all 75 patients, with no major complications. All patients showed clinical improvement through the resolution of ischemic symptoms and normalized interarm blood pressure differentials. These outcomes match those of prior reports of endovascular procedures, achieving nearly 100% success. During follow-up, 14 patients (18.7%) developed restenosis of the treated segment, which was confirmed by ultrasonography or angiography. Each case was successfully treated with repeated PTA to restore vessel patency. Percutaneous antegrade and retrograde endovascular approaches are safe and effective, providing durable midterm outcomes and representing preferred treatment options over open surgery for symptomatic SAS.
- 9 December 2025
- Published by Georg Thieme Verlag KG in Journal of Clinical Interventional Radiology ISVIR
- Vol. 10 (01) , 004-011
Open AccessPercutaneous Endovascular Approach to Symptomatic High-Grade Subclavian Artery Stenosis: A Retrospective Analysis
Subclavian artery stenosis (SAS) commonly causes upper limb ischemia and cerebrovascular insufficiency. Percutaneous transluminal angioplasty (PTA) and stenting have emerged as the preferred minimally invasive alternatives to surgical revascularization. This study aimed to evaluate the safety, efficacy, and midterm outcomes of antegrade and retrograde endovascular approaches for symptomatic SAS. This retrospective single-center analysis included 75 patients (45 men and 30 women; mean age, 65.3 years) treated between 2015 and 2023. The average follow-up period was 33.6 months (range, 20–52). The clinical characteristics, procedural techniques, and outcomes were retrospectively reviewed and analyzed. Technical success was achieved in all 75 patients, with no major complications. All patients showed clinical improvement through the resolution of ischemic symptoms and normalized interarm blood pressure differentials. These outcomes match those of prior reports of endovascular procedures, achieving nearly 100% success. During follow-up, 14 patients (18.7%) developed restenosis of the treated segment, which was confirmed by ultrasonography or angiography. Each case was successfully treated with repeated PTA to restore vessel patency. Percutaneous antegrade and retrograde endovascular approaches are safe and effective, providing durable midterm outcomes and representing preferred treatment options over open surgery for symptomatic SAS.
- Open Access
- 23 September 2025
- Published by Elsevier in IHJ Cardiovascular Reports
- Vol. 9 (3) , 54-58
Primary percutaneous coronary intervention of a segmentally unprotected left anterior descending artery with prior coronary artery bypass grafting surgery: a rare culprit lesion
- 23 September 2025
- Published by Elsevier in IHJ Cardiovascular Reports
- Vol. 9 (3) , 54-58
Open AccessPrimary percutaneous coronary intervention of a segmentally unprotected left anterior descending artery with prior coronary artery bypass grafting surgery: a rare culprit lesion
- Open Access
- 7 February 2025
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 6 (2) , 155-159
Early Saphenous Venous Graft Pseudoaneurysm, a Rare Cause of Acute Coronary Syndrome: Too Early or Too Late—A Management Dilemma
A saphenous vein graft (SVG) is a bypass conduit that is frequently employed in surgical revascularization operations. One of the primary issues with SVGs is that they can encounter blockage rates of up to 25% within the first year. Saphenous venous graft aneurysms (SVGAs) are extremely uncommon, yet they can develop at any time. While early SVG degeneration may result in SVGAs, the classic indications of myocardial ischemia are often associated with late SVG degeneration. Other methods of imaging, including coronary computed tomography and graft angiography, can detect SVGA that would otherwise go undetected. This issue may cause mortality to be underestimated, resulting in fatalities that go unnoticed and uninvestigated. The major goal of this case report was to offer a detailed account of an early SVGA episode in a patient who had a documented non-ST-segment myocardial infarction and significant myocardial ischemia, as confirmed by coronary artery angiotomography.
- 7 February 2025
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 6 (2) , 155-159
Open AccessEarly Saphenous Venous Graft Pseudoaneurysm, a Rare Cause of Acute Coronary Syndrome: Too Early or Too Late—A Management Dilemma
A saphenous vein graft (SVG) is a bypass conduit that is frequently employed in surgical revascularization operations. One of the primary issues with SVGs is that they can encounter blockage rates of up to 25% within the first year. Saphenous venous graft aneurysms (SVGAs) are extremely uncommon, yet they can develop at any time. While early SVG degeneration may result in SVGAs, the classic indications of myocardial ischemia are often associated with late SVG degeneration. Other methods of imaging, including coronary computed tomography and graft angiography, can detect SVGA that would otherwise go undetected. This issue may cause mortality to be underestimated, resulting in fatalities that go unnoticed and uninvestigated. The major goal of this case report was to offer a detailed account of an early SVGA episode in a patient who had a documented non-ST-segment myocardial infarction and significant myocardial ischemia, as confirmed by coronary artery angiotomography.
- Open Access
- 20 December 2024
- Published by Elsevier in Indian Heart Journal
- Vol. 77 (1) , 14-21
ANti-Thrombotic strAtegy for the management of nonocclusive thRombus with ST-segment elevation myocardial infarCtion in young pAtients – ANTARTICA study
- 20 December 2024
- Published by Elsevier in Indian Heart Journal
- Vol. 77 (1) , 14-21
Open AccessANti-Thrombotic strAtegy for the management of nonocclusive thRombus with ST-segment elevation myocardial infarCtion in young pAtients – ANTARTICA study
- 23 June 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (8) , 1038-1048
Sino‐atrial nodal artery occlusion causing acute sinus node dysfunction after percutaneous coronary intervention: Case report and systematic review
Background: New antithrombotic medications and improved stent designs have reduced branch occlusion, although the sino‐atrial nodal artery (SANA) may still be occluded after a percutaneous coronary intervention (PCI), causing sinus node dysfunction (SND). Ischemic sinus nodes are usually asymptomatic but can cause sinus arrest sometimes requiring pacemaker placement. In rare cases, junctional escape rhythms, a manifestation of sinus exit blocks after PCI, can predict cardiogenic shock.Methods: We present a case study of a patient who underwent bifurcation PCI to the LMCA to the LCX but subsequently developed cardiogenic shock as a result of SND, a junctional escape rhythm required substantial inotropic support. This case offers an exemplification of a sparsely documented, yet infrequent manifestation of iatrogenic ischemic SND at an unorthodox site, the confluence of the LMCA‐LCX. In addition, we conducted a comprehensive analysis of 22 scholarly works pertaining to the subject of sinus node dysfunction (SND) subsequent to PCI resulting from ischemia caused by stenosis or occlusion of the SANA.Results: RCA was responsible for 96.1% of SND cases, whereas LCX was responsible for 3.9%. SND was asymptomatic in 49.3% of cases and junctional escape rhythm in 37.6% of symptomatic cases. 28% needed a temporary transvenous pacemaker, while 7.8% needed a permanent one. Interventional management recanalized the SANA in 5.2% of patients, restoring flow.Conclusion: Transient sino‐atrial node ischemia after PCI can cause acute SND. Before stent implantation, doctors should consider SND. Complete plaque evaluation around the SANA is needed before choosing the best PCI procedure.
- 23 June 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (8) , 1038-1048
Sino‐atrial nodal artery occlusion causing acute sinus node dysfunction after percutaneous coronary intervention: Case report and systematic review
Background: New antithrombotic medications and improved stent designs have reduced branch occlusion, although the sino‐atrial nodal artery (SANA) may still be occluded after a percutaneous coronary intervention (PCI), causing sinus node dysfunction (SND). Ischemic sinus nodes are usually asymptomatic but can cause sinus arrest sometimes requiring pacemaker placement. In rare cases, junctional escape rhythms, a manifestation of sinus exit blocks after PCI, can predict cardiogenic shock.Methods: We present a case study of a patient who underwent bifurcation PCI to the LMCA to the LCX but subsequently developed cardiogenic shock as a result of SND, a junctional escape rhythm required substantial inotropic support. This case offers an exemplification of a sparsely documented, yet infrequent manifestation of iatrogenic ischemic SND at an unorthodox site, the confluence of the LMCA‐LCX. In addition, we conducted a comprehensive analysis of 22 scholarly works pertaining to the subject of sinus node dysfunction (SND) subsequent to PCI resulting from ischemia caused by stenosis or occlusion of the SANA.Results: RCA was responsible for 96.1% of SND cases, whereas LCX was responsible for 3.9%. SND was asymptomatic in 49.3% of cases and junctional escape rhythm in 37.6% of symptomatic cases. 28% needed a temporary transvenous pacemaker, while 7.8% needed a permanent one. Interventional management recanalized the SANA in 5.2% of patients, restoring flow.Conclusion: Transient sino‐atrial node ischemia after PCI can cause acute SND. Before stent implantation, doctors should consider SND. Complete plaque evaluation around the SANA is needed before choosing the best PCI procedure.
- Open Access
- 17 June 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (3) , 303-307
The Effectiveness and Tolerability of Switching Patients from Sacubitril/Valsartan, ARNI to Perindopril in Heart Failure with Reduced Ejection Fraction: EFFICIENT Trial
Objectives: Heart failure with reduced ejection fraction (HFrEF) is an advancing illness that can be managed with various drugs. In this study, we present data on the tolerance of perindopril in patients with HFrEF who were switched from angiotensin receptor neprilysin inhibitor (ARNI) to perindopril because of issues with the former’s tolerability or increased medication costs. Methods: A total of 125 patients with HFrEF were switched to perindopril in this retrospective study carried out at the heart failure clinic. Of those, 109 patients had data accessible for a 6-month follow-up. The data of the patients who switched from ARNI to perindopril between June and December 2023 were collected. Data such as the New York Heart Association (NYHA) class, N-terminal pro hormone brain natriuretic peptide (NT-proBNP), and left ventricular ejection fraction (LVEF) were compared at baseline and 6-month follow- up with those collected after the switchover. Results: During the transition, the average age was 58 ± 13 years (mean ± standard deviation), the disease duration was 2.6 ± 1.4 years, and 29.6% of the patients were female. The average period of follow-up following the transition was 5.7 ± 1.5 months. The 6-minute walk distance (6MWD) reduced from 344 ± 106 to 319 ± 85 m ( P = .056), but the NT-pro BNP levels increased from 478 ± 170 to 490 ± 137 pg/mL ( P = .56) after the transfer. All patients continued to maintain their NYHA functional class after the transition, with no significant difference seen ( P = .37). There was a little improvement in LVEF from 40% ± 4% to 41.5% ± 5% ( P < .001) during the follow-up after the switchover. Following the transition, no changes were observed in vital indicators, serum electrolytes, and creatinine levels. All patients successfully tolerated the transition to perindopril. Conclusions: The transfer from ARNI to perindopril was both well tolerated and safe. The patients’ functional condition remained unchanged, as did their NT-pro BNP levels. A modest improvement in LVEF was noted. In India, switching from ARNI to perindopril is less expensive.
- 17 June 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (3) , 303-307
Open AccessThe Effectiveness and Tolerability of Switching Patients from Sacubitril/Valsartan, ARNI to Perindopril in Heart Failure with Reduced Ejection Fraction: EFFICIENT Trial
Objectives: Heart failure with reduced ejection fraction (HFrEF) is an advancing illness that can be managed with various drugs. In this study, we present data on the tolerance of perindopril in patients with HFrEF who were switched from angiotensin receptor neprilysin inhibitor (ARNI) to perindopril because of issues with the former’s tolerability or increased medication costs. Methods: A total of 125 patients with HFrEF were switched to perindopril in this retrospective study carried out at the heart failure clinic. Of those, 109 patients had data accessible for a 6-month follow-up. The data of the patients who switched from ARNI to perindopril between June and December 2023 were collected. Data such as the New York Heart Association (NYHA) class, N-terminal pro hormone brain natriuretic peptide (NT-proBNP), and left ventricular ejection fraction (LVEF) were compared at baseline and 6-month follow- up with those collected after the switchover. Results: During the transition, the average age was 58 ± 13 years (mean ± standard deviation), the disease duration was 2.6 ± 1.4 years, and 29.6% of the patients were female. The average period of follow-up following the transition was 5.7 ± 1.5 months. The 6-minute walk distance (6MWD) reduced from 344 ± 106 to 319 ± 85 m ( P = .056), but the NT-pro BNP levels increased from 478 ± 170 to 490 ± 137 pg/mL ( P = .56) after the transfer. All patients continued to maintain their NYHA functional class after the transition, with no significant difference seen ( P = .37). There was a little improvement in LVEF from 40% ± 4% to 41.5% ± 5% ( P < .001) during the follow-up after the switchover. Following the transition, no changes were observed in vital indicators, serum electrolytes, and creatinine levels. All patients successfully tolerated the transition to perindopril. Conclusions: The transfer from ARNI to perindopril was both well tolerated and safe. The patients’ functional condition remained unchanged, as did their NT-pro BNP levels. A modest improvement in LVEF was noted. In India, switching from ARNI to perindopril is less expensive.
- Open Access
- 14 June 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (4) , 350-354
An Unusual Primary Paraneoplastic Manifestation of Adenocarcinoma of Lung
Carcinoma of lung (CoL) is the fourth most common cancer in India. It is classified as either small-cell or non-small-cell lung cancer, with adenocarcinoma being the most common variant. CoL can present either as paraneoplastic or non-paraneoplastic manifestation. We discuss a case of a patient who had an abrupt onset of sustained ventricular tachycardia and was subsequently diagnosed with metastatic non-small cell lung cancer with no cardiac infiltrates.
- 14 June 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (4) , 350-354
Open AccessAn Unusual Primary Paraneoplastic Manifestation of Adenocarcinoma of Lung
Carcinoma of lung (CoL) is the fourth most common cancer in India. It is classified as either small-cell or non-small-cell lung cancer, with adenocarcinoma being the most common variant. CoL can present either as paraneoplastic or non-paraneoplastic manifestation. We discuss a case of a patient who had an abrupt onset of sustained ventricular tachycardia and was subsequently diagnosed with metastatic non-small cell lung cancer with no cardiac infiltrates.
- Open Access
- 13 June 2024
- Published by Elsevier in Indian Heart Journal
- Vol. 76 (3) , 207-209
Role of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study
- 13 June 2024
- Published by Elsevier in Indian Heart Journal
- Vol. 76 (3) , 207-209
Open AccessRole of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study
- Open Access
- 14 May 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (3) , 287-291
Early Postoperative Iatrogenic Acute Type-A Aortic Dissection Following Off-pump Coronary Artery Bypass Graft Surgery: An Uncommon Complication of a Common Surgery
Complications of cardiac surgery include iatrogenic acute aortic dissection (IAAD), which occurs in 0.04%–0.06% of cases and has poorer results than spontaneous dissection. IAADs generated by thoracotomy are often associated with severe cardiovascular conditions, such as advanced atherosclerosis with three or more coronary artery lesions and persistent heart failure due to multivalvular heart disease. It is possible to experience this complication following any kind of cardiac surgery, including off-pump coronary artery bypass grafting (OPCAB) as well as following endovascular operations. We encountered early postoperative IAAD following OPCAB, which necessitated high-risk reoperation with dismal outcomes. Death rates could be reduced with better access to timely diagnosis and adequate treatment. Avoiding, diagnosing, and treating this potentially fatal complication requires tremendous effort from every member of the heart team.
- 14 May 2024
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (3) , 287-291
Open AccessEarly Postoperative Iatrogenic Acute Type-A Aortic Dissection Following Off-pump Coronary Artery Bypass Graft Surgery: An Uncommon Complication of a Common Surgery
Complications of cardiac surgery include iatrogenic acute aortic dissection (IAAD), which occurs in 0.04%–0.06% of cases and has poorer results than spontaneous dissection. IAADs generated by thoracotomy are often associated with severe cardiovascular conditions, such as advanced atherosclerosis with three or more coronary artery lesions and persistent heart failure due to multivalvular heart disease. It is possible to experience this complication following any kind of cardiac surgery, including off-pump coronary artery bypass grafting (OPCAB) as well as following endovascular operations. We encountered early postoperative IAAD following OPCAB, which necessitated high-risk reoperation with dismal outcomes. Death rates could be reduced with better access to timely diagnosis and adequate treatment. Avoiding, diagnosing, and treating this potentially fatal complication requires tremendous effort from every member of the heart team.